Ligand Pharmaceuticals Inc
LGND133.280USD
+0.560+0.42%
Market hours （ET）Quotes delayed by 15 min
2.57BMarket Cap
LossP/E TTM
More Details of Ligand Pharmaceuticals Inc Company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Company Info
Ticker SymbolLGND
Company nameLigand Pharmaceuticals Inc
IPO dateNov 18, 1992
CEOMr. Todd C. Davis
Number of employees68
Security typeOrdinary Share
Fiscal year-endNov 18
Address555 Heritage Drive, Suite 200
CityJUPITER
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code33458
Phone18585507500
Websitehttps://www.ligand.com/
Ticker SymbolLGND
IPO dateNov 18, 1992
CEOMr. Todd C. Davis
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
45.30K
-2.02%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
17.05K
-4.31%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.29K
+31.26%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
45.30K
-2.02%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
17.05K
-4.31%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Other
12.02M
26.52%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Other
12.02M
26.52%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.86%
The Vanguard Group, Inc.
10.63%
Janus Henderson Investors
5.33%
Macquarie Investment Management
4.70%
Dimensional Fund Advisors, L.P.
3.86%
Other
61.62%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.86%
The Vanguard Group, Inc.
10.63%
Janus Henderson Investors
5.33%
Macquarie Investment Management
4.70%
Dimensional Fund Advisors, L.P.
3.86%
Other
61.62%
Shareholder Types
Shareholders
Proportion
Investment Advisor
57.94%
Investment Advisor/Hedge Fund
37.89%
Individual Investor
2.39%
Research Firm
1.84%
Pension Fund
1.60%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.28%
Hedge Fund
0.05%
Insurance Company
0.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
534
19.71M
102.14%
-793.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
2023Q1
528
16.47M
96.50%
-1.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
2.67M
13.86%
-26.33K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
2.05M
10.63%
-29.89K
-1.44%
Mar 31, 2025
Janus Henderson Investors
1.03M
5.33%
+12.53K
+1.23%
Mar 31, 2025
Macquarie Investment Management
906.23K
4.7%
+21.85K
+2.47%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
744.93K
3.86%
+21.91K
+3.03%
Mar 31, 2025
State Street Global Advisors (US)
727.13K
3.77%
-16.51K
-2.22%
Mar 31, 2025
Congress Asset Management Company, LLP
642.71K
3.33%
+21.23K
+3.42%
Mar 31, 2025
Stephens Investment Management Group, LLC
607.22K
3.15%
-5.56K
-0.91%
Mar 31, 2025
Chicago Capital, LLC
554.52K
2.87%
+2.93K
+0.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
464.45K
2.41%
+26.01K
+5.93%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Pharmaceuticals ETF
3.03%
Virtus LifeSci Biotech Products ETF
1.91%
SPDR S&P Pharmaceuticals ETF
1.86%
Franklin Genomic Advancements ETF
1.68%
Invesco S&P SmallCap Health Care ETF
1.57%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.34%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.32%
iShares U.S. Pharmaceuticals ETF
1.1%
First Trust Multi-Manager Small Cap Opportunities ETF
0.71%
Simplify Health Care ETF
0.52%
View more
Invesco Pharmaceuticals ETF
Proportion3.03%
Virtus LifeSci Biotech Products ETF
Proportion1.91%
SPDR S&P Pharmaceuticals ETF
Proportion1.86%
Franklin Genomic Advancements ETF
Proportion1.68%
Invesco S&P SmallCap Health Care ETF
Proportion1.57%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.34%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.32%
iShares U.S. Pharmaceuticals ETF
Proportion1.1%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.71%
Simplify Health Care ETF
Proportion0.52%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
